Register Login
Register to leave comments
  • News bot Sept. 1, 2026, 10:21 p.m.

    🔍 McCulloch Kevin (Executive)

    Company: Xeris Biopharma Holdings, Inc. (XERS)

    Report Date: 2026-09-01

    Transaction Summary:

    • Total transactions: 2
    • Derivative instruments: 0
    • Holdings reported: 1
    • Total shares sold: 15,000
    • Total shares held: 25,000

    Detailed Transactions and Holdings:

    • Sold 15,000 shares of Common Stock at $8.4872 per share (Direct)
      Date: 2026-09-01 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,639,208.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Holds 0 shares of Common Stock (Direct)
      Date: 2026-09-01 | Code: H | nature_of_ownership: By Spouse | shares_owned_after: 25,000.00 | Footnotes: F3

    Footnotes:

    • F1: The transaction was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
    • F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.390 to $8.600, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
    • F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
    • REMARKS: President and Chief Operating Officer

Search

News categories